Conservative Long-Term Treatment of Chronic Renal Failure with Keto Acid and Amino Acid Supplementation

1987 ◽  
Vol 14 (5) ◽  
pp. 34-38
Author(s):  
R. Schmicker ◽  
K. Vetter ◽  
K. Lindenau ◽  
P.T. Fröhling ◽  
F. Kokot
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Amino Acid ◽  
Term Treatment ◽  
Amino Acid Supplementation ◽  
Keto Acid ◽  
Acid Supplementation ◽  
Long Term Treatment

Serum 25-Hydroxyvitamin D in Patients with Chronic Renal Failure on Long-Term Treatment with High Doses of Vitamin D2

Nephron ◽  
1980 ◽  
Vol 26 (3) ◽  
pp. 116-120
Author(s):  
Peter Teodor Fröhling ◽  
Franciszek Kokot ◽  
Karl Vetter ◽  
Jadwiga Kuska ◽  
Ingrid Kaschube ◽  
...  
Keyword(s):  
Vitamin D ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Term Treatment ◽  
Hydroxyvitamin D ◽  
Long Term Treatment ◽  
25 Hydroxyvitamin D ◽  
High Doses

scholarly journals Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion

Pharmaceutics ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 714
Author(s):  
Sung Hun Bae ◽  
Sun-Young Chang ◽  
So Hee Kim
Keyword(s):  
Rheumatoid Arthritis ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Hepatic Metabolism ◽  
Term Treatment ◽  
Concentration Time ◽  
Long Term Treatment ◽  
Total Body ◽  
Body Clearance

Tofacitinib is a Jak inhibitor developed as a treatment for rheumatoid arthritis. Tofacitinib is metabolized mainly through hepatic CYP3A1/2, followed by CYP2C11. Rheumatoid arthritis tends to increase renal toxicity due to drugs used for long-term treatment. In this study, pharmacokinetic changes of tofacitinib were evaluated in rats with gentamicin (G-ARF) and cisplatin-induced acute renal failure (C-ARF). The time-averaged total body clearance (CL) of tofacitinib in G-ARF and C-ARF rats after 1-min intravenous infusion of 10 mg/kg was significantly decreased by 37.7 and 62.3%, respectively, compared to in control rats. This seems to be because the time-averaged renal clearance (CLR) was significantly lower by 69.5 and 98.6%, respectively, due to decreased creatinine clearance (CLCR). In addition, the time-averaged nonrenal clearance (CLNR) was also significantly lower by 33.2 and 57.4%, respectively, due to reduction in the hepatic CYP3A1/2 and CYP2C11 subfamily in G-ARF and C-ARF rats. After oral administration of tofacitinib (20 mg/kg) to G-ARF and C-ARF rats, both CLR and CLNR were also significantly decreased. In conclusion, an increase in area under plasma concentration-time curves from time zero to time infinity (AUC) of tofacitinib in G-ARF and C-ARF rats was due to the significantly slower elimination of tofacitinib contributed by slower hepatic metabolism and urinary excretion of the drug.

Effect of essential amino acid supplementation in acute renal failure

1995 ◽  
Vol 27 (4) ◽  
pp. 503-510 ◽  
Author(s):  
M. Z. Mocan ◽  
H. Mocan ◽  
M. N. Gacar ◽  
G. K. Özgür ◽  
M. H. Uluutku
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Amino Acid ◽  
Essential Amino Acid ◽  
Amino Acid Supplementation ◽  
Acid Supplementation

scholarly journals Oxaliplatin for Metastatic Colon Cancer in a Patient with Renal Failure

2008 ◽  
Vol 2 ◽  
pp. CMO.S412
Author(s):  
Kenji Katsumata ◽  
Tetsuo Sumi ◽  
Tatehiko Wada ◽  
Yasuharu Mori ◽  
Masayuki Hisada ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Renal Failure ◽  
Term Treatment ◽  
Pharmacokinetic Data ◽  
Metastatic Colon Cancer ◽  
Standard Regimen ◽  
Long Term Treatment ◽  
Before And After ◽  
Cecal Cancer

Objective Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available in Japan. In a hemodialysis patient with cecal cancer, we investigated the efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin. Methods A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m2) and l-leucovorin(l-LV) (200 mg/m2), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively. Then 5-FU (400 mg/m2) was administered rapidly via the side tube, followed by 5-FU (2,000 mg/m2) over 46 hours via the main tube. The patient had chronic renal failure due to diabetic nephropathy and hemodialysis was performed 3 times a week. Blood samples were collected from the dialyzer before and after each hemodialysis session to examine platinum clearance. Results The patient received 3 courses of oxaliplatin before he died of cancer. During hemodialysis, the platinum level fell from 0.32 μg/mL to 0.15 μg/mL. Conclusion Since patients with renal failure have various associated disorders and oxaliplatin has a long half-life, it is necessary to obtain more pharmacokinetic data to investigate its accumulation and dialysability during long-term treatment. Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document